Helmholtz Gemeinschaft


Myelin-oligodendrocyte glycoprotein antibody-associated disease

Item Type:Article
Title:Myelin-oligodendrocyte glycoprotein antibody-associated disease
Creators Name:Marignier, R. and Hacohen, Y. and Cobo-Calvo, A. and Pröbstel, A.K. and Aktas, O. and Alexopoulos, H. and Amato, M.P. and Asgari, N. and Banwell, B. and Bennett, J. and Brilot, F. and Capobianco, M. and Chitnis, T. and Ciccarelli, O. and Deiva, K. and De Sèze, J. and Fujihara, K. and Jacob, A. and Kim, H.J. and Kleiter, I. and Lassmann, H. and Leite, M.I. and Linington, C. and Meinl, E. and Palace, J. and Paul, F. and Petzold, A. and Pittock, S. and Reindl, M. and Sato, D.K. and Selmaj, K. and Siva, A. and Stankoff, B. and Tintore, M. and Traboulsee, A. and Waters, P. and Waubant, E. and Weinshenker, B. and Derfuss, T. and Vukusic, S. and Hemmer, B.
Abstract:Myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder that presents in both adults and children as CNS demyelination. Although there are clinical phenotypic overlaps between MOGAD, multiple sclerosis, and aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder (NMOSD) cumulative biological, clinical, and pathological evidence discriminates between these conditions. Patients should not be diagnosed with multiple sclerosis or NMOSD if they have anti-MOG antibodies in their serum. However, many questions related to the clinical characterisation of MOGAD and pathogenetic role of MOG antibodies are still unanswered. Furthermore, therapy is mainly based on standard protocols for aquaporin-4 antibody-associated NMOSD and multiple sclerosis, and more evidence is needed regarding how and when to treat patients with MOGAD.
Keywords:Autoantibodies, Biomarkers, CNS Demyelinating Autoimmune Diseases, Immunologic Factors, Myelin-Oligodendrocyte Glycoprotein
Source:Lancet Neurology
Publisher:Elsevier / Lancet
Page Range:762-772
Date:September 2021
Additional Information:Erratum in: Lancet Neurol 20(10):e6. Erratum in: Lancet Neurol 21(1):e1. Copyright © 2021 Elsevier Ltd. All rights reserved.
Official Publication:https://doi.org/10.1016/S1474-4422(21)00218-0
External Fulltext:View full text on external repository or document server
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library